Heart Failure Therapeutics Market

Heart failure (HF), often referred to as congestive heart failure (CHF), is when the heart is unable to pump sufficiently to maintain blood flow to meet the body's needs. Signs and symptoms commonly include shortness of breath, excessive tiredness, and leg swelling.The shortness of breath is usually worse with exercise, while lying down, and may wake the person at night.A limited ability to exercise is also a common feature. Chest pain, including angina, does not typically occur due to heart failure.

Heart Failure Therapeutics Market contains market size and forecasts of Heart Failure Therapeutics in Global, including the following market information:

• Global Heart Failure Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global top five companies in 2021 (%)

The global Heart Failure Therapeutics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Diagnosis Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Heart Failure Therapeutics include Bayer, Cynokinetics, Les Laboratoires Servier, Merck & Co., Novartis, Procoralan, Bristol-Myers Squibb Company, Cardiorentis AG and CVie Therapeutics Limited, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Heart Failure Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Heart Failure Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Heart Failure Therapeutics Market Segment Percentages, by Type, 2021 (%)

• Diagnosis
• Prognosis
• Treatment Options and Treatment Algorithm

Global Heart Failure Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Heart Failure Therapeutics Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Clinic
• Medical Research Organization

Global Heart Failure Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Heart Failure Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Heart Failure Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Heart Failure Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Bayer
• Cynokinetics
• Les Laboratoires Servier
• Merck & Co.
• Novartis
• Procoralan
• Bristol-Myers Squibb Company
• Cardiorentis AG
• CVie Therapeutics Limited
• Orion Corporation
• PhaseBio Pharmaceuticals
• Market Segment by Product Type
• B-Blockers
• Calcium Channel Blockers
• Cardiac Glycosides
• Diuretics
• Morphine
• Vasodilators/Nitrates